Core Insights - Akari Therapeutics is focused on developing next-generation precision bi-functional antibody drug conjugates (ADCs) for cancer treatment [2][3] - The company has appointed Abizer Gaslightwala as the new President and CEO, who shares his vision for the company's future [2] Company Overview - Akari Therapeutics utilizes an innovative ADC discovery platform to create novel bi-functional ADC candidates aimed at targeting various cancers [3] - The lead candidate, AKTX-101, targets the TROP2 receptor on cancer cells and employs a proprietary linker to deliver a novel PH1 payload directly into tumors [3] - PH1 is designed to disrupt RNA splicing within cancer cells, inducing tumor-specific cell death while minimizing off-target toxicity [3] - Preclinical studies indicate that AKTX-101 has superior activity, prolonged survival, less resistance, and better tolerability compared to current ADCs [3] - The candidate has shown potential for synergy with checkpoint inhibitors and has demonstrated prolonged survival in preclinical models [3] Future Directions - The company is generating validating data on its novel payloads to advance its pipeline [3]
Akari Therapeutics Releases Welcome Video from Newly Appointed Chief Executive Officer, Abizer Gaslightwala